Cerebral changes in hepatic encephalopathy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 7, 1998, Pages 752-760

  Watanabe, Akiharu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Automated polysomnography; Brain image; Evoked potentials; Liver cirrhosis; Neuropsychological test; SPECT; Subclinical hepatic encephalopathy; Topography

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; PHOSPHATIDYLCHOLINE;

COMA; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS; ELECTROENCEPHALOGRAM; EVOKED CORTICAL RESPONSE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031723137     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00728.x     Document Type: Review

References (56)

1. Adams RD, Foley JM. The neurological disorder associated with liver disease. Assoc. Res. New Ment. Dis. Proc. 1953; 32: 198-237.
2. Norenberg MD. The role of astrocytes in hepatic encephalopathy. Neurochem. Pathol. 1987; 6: 13-29.
3. Sherlock S. Diseases of the Liver and Biliary System, 6th edn. Blackwell Scientific Publications: London, 1981; 91-106.
4. Zenerolli ML, Cioni G, Crisi G, Vezzelli C, Ventura E. Globus pallidus alterations and brain atrophy in liver cirrhosis patients with encephalopathy. An MR imaging study. Magn. Reson. Imaging 1991; 9: 295-302.
5. Tater RE, Switala J, Arria A, Plail J, Van Thiel DH. Subclinical hepatic encephalopathy. Transplantation 1990; 50: 632-7.
6. Davies MG, Rowan MJ, McMathuna P, Kelling PW, Weir DG, Feely J. The auditory P300 event-related potential. An objective marker of the encephalopathy of chronic liver disease. Hepatology 1990; 12: 688-94.
7. Kamijo K, Kiyuna T, Yamazaki T. Multiple equivalent current dipole localization for multichannel EEG/MEG data: An NNN (neural network and numerical analysis) approach. In: 8th RAMP Symposium, Tokyo, 1996; 65-78.
8. Zeneroli ML, Cioni G, Vezzelli C et al. Prevalence of brain atrophy in liver cirrhosis patients with chronic persistent encephalopathy. J. Hepatol. 1987; 4: 283-92.
9. Rikkers L, Jenko P, Ruduman D, Freides D. Subclinical hepatic encephalopathy: Detection, prevalence and relationship to nitrogen metabolism. Gastroenterology 1978; 75: 462-9.
10. Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Döll W. Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig. Dis. Sci. 1981; 26: 622-30.
11. Watanabe A, Yoshida Y, Nagashima H. Pathophysiology and prognosis of subacute hepatitis. Med. Postgrad. 1988; 26: 351-7.
12. Gitlin N. Subclinical portal-systemic encephalopathy. Am. J. Gastroenterol. 1988; 83: 8-11.
13. Kügler CF, Lotterer E, Petter J et al. Visual event-related P300 potentials in early portosystemic encephalopathy. Gastroenterology 1992; 103: 302-10.
14. Watanabe A, Kuwabara Y, Okita H et al. Computer-assisted quantitative neuropsychological tests for diagnosing subclinical hepatic encephalopathy in patients with liver cirrhosis. In: Record C, Al-Mardini H, eds. Advances in Hepatic Encephalopathy and Metabolism in Liver Disease. Newcastle: Ipswich Books, 1997; 475-9.
15. Morgan M, Lockwood A. Definition and assessment of subclinical hepatic encephalopathy. In: International Symposium on Hepatocerebral Disorders September 20 1997. Val David, Canada.
16. Schomerus H, Schreiegg J. Prevalence of latent portasystemic encephalopathy in an unselected population of patients with liver cirrhosis in general practice. J. Gastroenterol. 1993; 31: 231-4.
17. Moore JW, Dunk AA, Crawford JR et al. Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. J. Hepatol. 1989; 9: 319-25.
18. Quero JC, Hartmann IJC, Meulstee J, Hop WCJ, Schalm SW. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology 1996; 24: 556-60.
19. Yen CL, Liaw YF. Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy. Hepatogastroenterology 1990; 37: 332-4.
20. Van Der Rijt CCD, Schalm SW, De Groot GH, De Vlieger M. Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Eleciroencephal. Clin. Neurophysiol. 1984; 57: 423-6.
21. Robin ED,Travis DM, Bromberg PA, Forkner CE Jr,Tyler JM. Ammonia excretion by mammalian lung. Science 1985; 129: 270-1.
22. Wakabayashi H, Kuwabara Y, Murata H, Kobashi K, Watanabe A. Measurement of the expiratory ammonia concentration and its clinical significance. Metab. Brain Dis. 1997; 12: 161-9.
23. Watanabe A, Tsuchida T, Yata Y, Kuwabara Y. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metabol. Brain Dis. 1995; 10: 239-48.
24. Sanyal AJ, Freedoman AM, Shiffman ML, Purdum PP III, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt; Results of a prospective controlled study. Hepatology 1994; 20: 46-55.
25. Gubbins GP, Moritz TE, Marzano LS, Talwalkar R, McClain CJ, Mendenhall CL. Helicobacter pylori is a risk factor for hepatic encephalopathy in acute alcoholic hepatitis; The ammonia hypothesis revisited. Am. J. Gastroenterol. 1993; 88: 1906-10.
26. Cosme Jimenez A, Bujanda Fernandez de Pierola L, Poch Zapirain M, Orcolaga Alba R, Ojeda Perez E, Arenas Mirave JI. Congenital intrahepatic venous shunt as a cause of hepatic encephalopathy. Gastroenterol. Hepatol. 1995; 18: 460-3.
27. Takatama S. Hepatic encephalopathy in the aged-patients to be differentiated from dementia. Med. Tribune 1989; 21: 52-3 (in Japanese).
28. Uchino T, Endo F, Ikeda S, Shiraki K, Sera Y, Matsuda I. Three brothers with progressive hepatic dysfunction and severe hepatic steatosis due to a patent ductus venosus. Gastroenterology 1996; 110: 1964-8.
29. Watanabe A. Pathophysiology. Subclinical Hepatic Encephalopathy: Diagnosis and Treatment. Watanabe A, ed. Tokyo; Medical Review Inc., 1993; 31-65 (in Japanese).
30. Boon AP, Adams DH, Buckels JAC, McMaster P. Neuropathological findings in autopsies after liver transplantation. Transplant. Proc. 1991; 23: 1471-2.
31. Kullmann F, Hollerbach S, Holstege A, Schölmerich J. Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials. J. Hepatol. 1995; 22: 101-10.
32. Sagalés T, Gimeno V, de al Calzada MD, Casellas F, Dolors Macia M, Villar Soriano M. Brain mapping analysis in patients with hepatic encephalopathy. Brain Topography 1990; 2: 221-8.
33. Higuchi K, Shimizu Y, Nambu S et al. Effects of an infusion of branched chain amino acids on neurophysiological and psychometric testings in cirrhotic patients with mild hepatic encephalopathy. J. Gastroenterol. Hepatol. 1994; 9: 366-72.
34. Saitoh O, Niwa S, Hiramatsu K, Kameyama T, Rymar K, Itoh K. Abnormalities in late positive components of event-related potentials may reflect a genetic predisposition to schizophrenia. Biol. Psych. 1984; 19: 293-303.
35. Horita M, Kim Y, Matsuura K, Yamaguchi N, Yamamoto G. A computer-aided polysomnograph analysis system. Jpn J. Electroencephal. Electromy. 1988; 16: 346-53 (in Japanese with English abstract).
36. Coon HO, Lieberthal M. The syndrome of portal-systemic encephalopathy. In: Coon HO, ed. The Hepatic Coma Syndromes and Lactulose. Baltimore: Williams and Wilkins, 1979; 1-45.
37. Cabrera J, Córdooba J, Lataif L, Blei AT. High prevalence of insomnia in compensated cirrhosis. A controlled survey. Hepatology 1996; 24: 452A.
38. Bakti G, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: Model experiments with triazolam. Hepatology 1987; 7: 629-38.
39. Inoue E, Hori S, Narumi Y et al. Portal-systemic encephalopathy: Presence of basal ganglia lesions with high signal intensity on MR images. Radiology 1991; 179: 551-5.
40. Watanabe A, Murakami J, Ando T, Hioki O, Wakabayashi H, Higuchi K. Reduction of increased signal intensity in the basal ganglia on T1-weighted MR images during treatment of hepatic encephalopathy. Intern. Med. 1993; 32: 10-14.
41. Krieger D, Krieger S, Janaen O, Gass P, Theilmann L, Lichtnecker H. Manganese and chronic hepatic encephalopathy. Lancet 1995; 346: 270-4.
42. Norton NS, McConnell JR, Zetterman RK, Rodriguez-Sierra JF. A quantitative evaluation of magnetic resonance image signal changes of the brain in chronic hepatic encephalopathy. J. Hepatol. 1994; 21: 764-70.
43. Stehling MK, Turner R, Mansfield P. Echo-planar imaging: magnetic resonance imaging in a fraction of a second. Science 1991; 254: 43-50.
44. OnodaY. Neurological diseases from the aspect of SPECT. Bio Clinica 1996; 11: 256-9 (in Japanese).
45. 99mhexamethylpropylene amine oxime. Eur. J. Nucl. Med. 1993; 20: 391-401.
46. Shenton ME, Kikins R, Jolesz FA et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N. Engl. J. Med. 1992; 327: 604-12.
47. Ohnishi T, Hoshi H, Nagamachi S et al High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric disease. J. Nucl. Med. 1995; 36: 1163-9.
48. Häussinger D, Laubenberger J, Vom Dahl S et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypoosmolarity and hepatic encephalopathy. Gastroenterology 1994; 107: 1475-80.
49. James JH, Escourrou J, Fischer JE. Blood-brain neutral amino acid transport activity is increased after portacaval anastomosis. Science 1978; 200: 1395-7.
50. Watanabe A, Shiota T, Takei N, Fujiwara M, Nagasima H. Ammonia detoxication by accelerated oxidation of branched chain amino acids in brains of acute hepatic failure rats. Biochem. Med. Metabol. Biol. 1986; 35: 367-75.
51. Rössle M, Luft M, Herz R, Klein B, Lehmann M, Gerok W. Amino acid, ammonia and neurotransmitter concentrations in hepatic encephalopathy: serial analysis in plasma and cerebral fluid during treatment with an adapted amino acid solution. Klin. Wochenschr. 1984; 62: 867-75.
52. Watanabe A. Nutritional pharmacology of branched-chain amino acids as psychotropic action in liver cirrhosis. In: Okita K, ed. Frontiers in Hepatology. Tokyo: Axel Springer Japan Publishing Inc., 1995; 70-76.
53. Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, Yurgelun-Todd D, Babb SM. Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. JAMA 1995; 274: 902-7.
54. Wecker L. Neurochemical effects of choline supplementation. Can. J. Physiol. Pharmacol. 1986; 64: 329-33.
55. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicholine. Life Sci. 1995; 56: 637-60.
56. Zanotti A, Rubin R, Calderini G. Pharmacological properties of phosphatidylserine: Effects on memory function. In: Eddman WB, ed. Nutrients and Brain Function. Basel: Karger, 1987; 95-116.